



State of California-Health and Human Services Agency  
Department of Health Services



ARNOLD SCHWARZENEGGER  
Governor

DATE: September 27, 2006

CHDP Provider Information Notice No.: 06-12

TO: ALL CHILD HEALTH AND DISABILITY PREVENTION (CHDP)  
PROGRAM PROVIDERS AND MEDI-CAL MANAGED CARE PLANS

SUBJECT: THREE INFLUENZA VACCINE CHANGES FOR 2006-07

There are three changes for influenza vaccine for 2006-07:

1. The first change is that for 2006-07, all infants and children 6 months through 59 months are considered at increased risk of influenza infection or its complications, making them eligible for influenza vaccine as a CHDP program benefit because their age is a high risk factor. The Advisory Committee on Immunization Practices (ACIP) is extending their recommendation of 2003-04, that included healthy infants six to 24 months of age as at increased risk of influenza infection or its complications, to now include infants through 59 months.

The committee based the new recommendation on recent research that indicates flu causes much of the use of health care and lost work time by the parents of children ages two to five years, despite the small number of serious illnesses and deaths caused by the disease among those children. According to the committee, about 85 of every 1,000 four-year-old children receive physician care for flu annually. In addition, recent research indicates that flu vaccinations among children could help protect individuals at the highest risk for complications from the disease.

In addition to infants and children 6 months through 59 months, other high risk groups include:

- Children and adolescents aged 5 through 18 years with chronic disorders of the pulmonary or cardiovascular systems, including asthma.
- Children and adolescents aged 5 through 18 years who have required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus [HIV]).

## ALL CHDP PROGRAM PROVIDERS AND MEDICAL MANAGED CARE PLANS

Page 2

September 27, 2006

- Children and adolescents aged 5 through 18 years who have any condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or other neuromuscular disorders) that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk for aspiration.
  - Children and adolescents aged 5 through 18 years who are receiving long-term aspirin therapy and may therefore be at risk for developing Reye syndrome after influenza.
  - Children and adolescents aged 5 through 18 years who are residents of nursing homes and other chronic-care facilities that house persons at any age who have chronic medical conditions.
  - Adolescent females aged <19 years who will be pregnant during influenza season.
  - Children and adolescents aged 5 through 18 years who are household contacts of persons in the following high-risk groups:
    - a. any children less than five years old;
    - b. children or adolescents in any of the other groups listed above;
    - c. any person 50 years or older;
    - d. adults with chronic disorders of the pulmonary or cardiovascular systems;
    - e. adults who have required regular medical follow-up or hospitalization during the preceding year for chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or by HIV).
2. The second change is that effective July 1, 2006, it is against California law Code Section 124172) to administer doses of inactivated influenza vaccine from a multi-dose vial to pregnant women or children younger than three years old because of the level of the mercury-containing preservative, thimerosal, contained in multi-dose vials. Effective July 1, 2006, only doses of influenza vaccine from single-dose syringes or vials with trace levels or no mercury may be given to these groups. This law does not apply to persons who are three years of age and older and who are not pregnant. Fluzone<sup>®</sup> influenza virus vaccine (Sanofi Pasteur, Inc.) in pre-filled 0.25

mL unit dose syringes is currently the only influenza virus vaccine approved for use in children aged six months to three years.

3. The third change is that an ACIP/VFC Resolution has identified all healthy children and adolescents, aged five years thru 18 years 11 months, as eligible for FluMist (Live Attenuated Influenza Vaccine). Therefore, the comment "Presence of household member(s) with high risk factor" has been removed as a requirement for FluMist, effective September 1, 2006.

Your continuing participation in the CHDP Program is greatly appreciated. If you have any questions about this Provider Information Notice or other CHDP issues, please contact your local CHDP Program office.

Sincerely,

**Original Signed by Marian Dalsey**

Marian Dalsey, M.D., M.P.H., Chief  
Children's Medical Services Branch  
Enclosure

**CHDP Vaccine Codes and Rates  
September 1, 2006**

Vaccine	Code	Vaccine Source	Age	Rate <sup>1</sup>	Comment Required
DTaP	45	Vaccines For Children (VFC)	2 months thru 6 years, 11 months	\$ 9.00	
DT Pediatric	59	Purchased	2 months thru 6 years, 11 months	\$ 10.93	
Td Adult (DECAVAC™)	58	VFC	7 years thru 18 years 11 months	\$ 9.00	
Td Adult	60	Purchased	7 years thru 20 years, 11 months	\$ 13.96	
Tdap	72	VFC	10 years thru 18 years 11 months	\$ 9.00	
Hepatitis A	65	VFC (Pediatric)	1 year thru 18 years, 11 months	\$ 9.00	
	66	Purchased (Adult)	19 years thru 20 years, 11 months	\$ 65.48	
HBIG <sup>2</sup>	41 + 57	Purchased	Birth thru 20 years, 11 months	\$ 168.12	Reason for administration
Hepatitis B/Hib Combination	56	VFC	2 months thru 4 years, 11 months	\$ 9.00	
Hepatitis B Lower Dose (Pediatric/Adolescent)	40	VFC	Birth thru 18 years, 11 months	\$ 9.00	
Hepatitis B Higher Dose (Adult)	42	VFC	11 years thru 15 years, 11 months <sup>3</sup>	\$ 9.00	(Use this code for two dose adolescent schedule)
Hepatitis B	51	Purchased	19 years thru 20 years, 11 months	\$ 38.17	
Hib	38	VFC	2 months thru 18 years, 11 months	\$ 9.00	High risk factor, if older than 5 years
	63	Purchased	19 years thru 20 years, 11 months	\$ 16.82	High risk factor
Influenza	53	VFC	6 months thru 18 years, 11 months	\$ 9.00	High risk factor
	54	Purchased	6 months thru 20 years, 11 months	\$ 13.76	High risk factor
FluMist <sup>4</sup>	71	VFC	5 years thru 18 years, 11 months	\$ 9.00	

1. Total reimbursement, includes administration fee.
2. Only for infants with HBsAg (+) mothers and for children exposed to known/suspected HBsAg (+) blood/tissue fluids.
3. Adolescent two dose immunization schedule, currently approved for ages 11 years thru 15 years, 11 months.
4. For one dose annually, except for children 5 years through 8 years, 11 months who have never received an influenza immunization. These children should receive two doses, with an interval of 42 days.

## CHDP Vaccine Codes and Rates

Vaccine	Code	Vaccine Source	Age	Rate <sup>1</sup>	Comment Required
MMR	33	VFC	12 months thru 18 years, 11 months	\$ 9.00	
	48	Purchased	19 years thru 20 years, 11 months	\$ 38.27	
MMRV	74	VFC	12 months thru 18 years, 11 months	\$ 9.00	
Measles <sup>4a</sup>	34	Purchased	12 months thru 20 years, 11 months <sup>5</sup>	\$ 21.29	Reason for administration
Meningococcal Conjugate Vaccine (MCV4)	69	VFC	11 years thru 18 years 11 months	\$ 9.00	
	70 + 73	Purchased	19 years thru 20 years 11 months	\$ 101.84	
Pediarix <sup>TM</sup>	68	VFC	2 months thru 6 years, 11 months	\$ 9.00	
Polio – Inactivated	39	VFC	2 months thru 18 years, 11 months	\$ 9.00	
	64	Purchased	19 years thru 20 years, 11 months	\$ 29.84	High risk factor
Pneumococcal Polysaccharide (23PS)	55	Purchased	2 years thru 20 years, 11 months	\$ 20.74	High risk factor
Pneumococcal, heptavalent (Prevnar)	67	VFC	1 month thru 4 years, 11 months	\$ 9.00	
Rotavirus <sup>6</sup>	75	VFC	6 weeks thru 32 weeks	\$ 9.00	
Rubella <sup>7</sup>	36	Purchased	12 months thru 20 years, 11 months	\$ 24.50	Reason for administration
Varicella	46	VFC	12 months thru 18 years, 11 months	\$ 9.00	
	52	Purchased	19 years thru 20 years, 11 months	\$ 48.94	

1. Total reimbursement, includes administration fee.
- 4a. For individuals with a contraindication to rubella or mumps vaccine.
5. Measles vaccine (or, if not available, MMR) is recommended in children as young as 6 months, in outbreak situations or for international travel.
6. Oral vaccine.
7. For individuals with a contraindication to measles or mumps vaccine.